Introduction
Aminoglycosides are potent bactericidal agents that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. They are often used in combination with either beta-lactam or glycopeptides, especially for the treatment of complicated staphylococcal infections, as these drugs act synergically [1] . The main mechanism of aminoglycoside resistance in staphylococci is drug inactivation by cellular aminoglycoside-modifying enzymes (AMEs), which are categorized into four classes depending on the modifications they induce: acetyltransferases (AACs), phosphotransferases (APHs), nucleotidyltransferases (ANTS), and adenyltransferases (AADs). Among staphylococci, the most common AME is 6′-Nacetyltransferase-2″-O-phosphotransferase [AAC(6′)-APH (2″)], encoded by the aac(6′)-Ie-aph(2″) gene inactivating gentamicin, kanamycin, tobramycin, neomycin, and amikacin. 4′-O-adenyltransferase I [ANT(4′)-I] is encoded by ant(4′)-Ia gene and inactivates kanamycin, neomycin, tobramycin and amikacin. Finally, 3′-O-phosphotransferase III [APH(3′)-III] is encoded by aph(3′)-IIIa and inactivates kanamycin and amikacin [2] .
Despite the high incidence of aminoglycoside resistance among methicillin-resistant staphylococci as reported before 2000, there is currently little information on the incidence and predominant types of AMEs in many countries. This lack of information is generally of great importance, particularly for Greece, where the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCoNS) is high in correlation with the fact that, in recent years, aminoglycosides and specifically amikacin and gentamicin are widely used in our clinical settings.
The aim of the present study was to provide information regarding the prevalence of AMEs in correlation with the rate of aminoglycoside-resistance among staphylococcal isolates collected from five different Greek hospitals during 2009, in order to define a baseline for monitoring possible future increase. 
Materials and methods

Bacterial
Molecular methods
Detection of mecA, aac(6′)-Ie-aph(2″), ant(4′)-Ia and aph (3′)-IIIa genes was performed by the multiplex PCR protocol described by Choi et al. [3] . Clones of representative MRSA and MRSE strains with different phenotypes and genotypes were defined by multi-locus sequence typing (MLST) (http://www.mlst.net).
Susceptibility testing All isolates were tested for resistance to aminoglycosides by a disk diffusion method using amikacin 30 μg, gentamicin 10 μg, tobramycin 10 μg and kanamycin 30 μg, according to the Clinical and Laboratory Standards Institute guidelines [4] . Determination of MICs to the above aminoglycosides was done by Etest (AB Biodisk, Solna, Sweden), according to the manufacturer's instructions. All isolates were also tested for their susceptibility to various antimicrobial agents by the use of the VITEK 2 P549 card.
Statistical analysis
The effects of distribution of AME genes and regions, as well as their interactions, were examined using a log-linear model, and the significance levels of the individual comparisons (post-hoc tests) were adjusted using the Bonferroni's correction. The analysis was performed using GLIM3.77 (Royal Statistical Society).
Results
According to PCR results, 592 S. aureus (48.2%) carried any of the AMEs genes: 434 isolates, including 420 methicillin-resistant and 14 methicillin-sensitive (73.3% of PCR-positive), carried the aph(3′)-IIIa gene, and 81 isolates, including 79 methicillin-resistant and 2 methicillin-sensitive (13.7% of PCR-positive), carried the ant(4′)-Ia gene, whereas, 77 isolates, all methicillinresistant (13% of PCR-positive), carried the aac(6′)-Ie-aph (2″). No coexistence of two or more AME genes was detected in any S. aureus strain. No direct correlation between sequence types (STs) and AME gene carriage was found. The great majority of ST80 and ST7 MRSA carried the aph(3′)-IIIa, while strains of ST239 (the main nosocomial clone), ST377 and ST225, carried either the ant(4′)-Ia gene or the aac(6′)-Ie-aph(2″) one. Strains of ST1 and ST30 did not carry any AME gene.
Susceptibility results based on the disk diffusion method revealed that among 1,228 S. aureus, 636 isolates (51.8%) were aminoglycoside-sensitive, whereas, the remaining 592 isolates (48.2%) were resistant to any of the aminoglycosides tested, i.e. 48.2% were resistant to amikacin, 48.2% to kanamycin, 12.9% to tobramycin and 6.3% to gentamicin. Among MRSA tested, 92.7% exhibited resistance to amikacin, 92.7% to kanamycin, 25% to tobramycin and 12.3% to gentamicin. Among MSSA 2.6% exhibited resistance to amikacin, 2.6% to kanamycin and 0.3% to tobramycin. None of the aminoglycoside-resistant strains lacked any of the AMEs genes, while a strong correlation between the resistant phenotypes and presence of AMEs genes was observed (100% concordance). Results by Etest correlated well with those obtained by the disk diffusion method. However, discrepancies on susceptibility testing results of the automated VITEK 2 were observed, i.e. whereas the system identified correctly all S. aureus strains carrying the aac(6′)-Ie-aph(2″) or ant(4′)-Ia gene, it failed to detect stains possessing only the aph(3′)-IIIa (Table 1 ).
An interesting finding was the significant differences observed on the distribution of AME genes among participating hospitals (Table 2) . Overall, there is a significant AME gene effect (P<0.01) in terms of distribution, whereas, the regions differ significantly (P<0.01) in terms of resistance. The interaction between the AME gene distribution effect and region effect is also significant (P< 0.01). More specifically, the AME gene distribution effect follows different patterns across regions or the region effect varies across AME gene distribution. In particular, in South-western Greece all AME gene comparisons were significant (P<0.01). In Northern Greece the distribution of the aph(3′) Even though the majority of aminoglycosideresistant MRSE belonged to ST2 and ST22, the main clones in Greece, polyclonality was observed among resistant genotypes without any correlation of clones to AME gene carriage.
Susceptibility results based on the disk diffusion method revealed that 430 isolates (42.8%) were simultaneously resistant to all four aminoglycosides tested. All isolates were methicillin-resistant; no MSSE was detected with resistance to any aminoglycosides. Etest and the VITEK 2 system identified correctly all aminoglycoside-resistant isolates. No significant differences on the rate of resistance (P=0.54) or on AME gene distribution (P=0.29) among the regions were observed.
Discussion
Although aminoglycosides retain activity against the majority of Gram-negative clinical bacterial isolates in many parts of the world, the relatively frequent occurrence of nephrotoxicity and ototoxicity during treatment make physicians reluctant to use these compounds in everyday practice [5] . The doubts regarding the actual clinical utility of aminoglycosides resulted in the use of other antimicrobial agents with improved safety [6] . However, the recent emergence of infections due to Gram-negative bacteria with advanced patterns of antimicrobial resistance has prompted physicians to reconsider these "old" antibacterial agents [7] . Aminoglycosides are also used in orthopaedic surgery, both locally and systemically, for prophylaxis of implant-related infections and treatment of skeletal infections. For local prophylaxis, application of gentamicin in the bone cement as well as coating of metallic implants with tobramycin or gentamicin appear to be effective, resulting in improved long-term implant survival [8] . For the treatment of skeletal infections, gentamicin-loaded bone cement beads, tobramycin impregnated beads and bone graft substitutes offer high concentrations of antibiotics at the site of infection [9] . Table 2 Distribution of AME genes among S. aureus isolates collected from three regions of Greece Region Total number of isolates AME gene distribution, n (%) AME-positive isolates, n (%) However, local usage of aminoglycosides could rapidly induce antibiotic resistance among staphylococci with subsequent reduced effect on prophylaxis [10] . Since CoNS and S. aureus are the leading causes of device-related infections, continued surveillance concerning the resistance of staphylococci to aminoglycosides is required. The rate of staphylococcal resistance to aminoglycosides varies from country to country and from year to year [2, [11] [12] [13] . In a European multicenter study during 1999, Schmitz et al. reported that 23%, 29% and 31% of S. aureus were resistant to gentamicin, tobramycin and kanamycin, respectively, whereas Hope et al. reported that 9% of MRSA and 2.5% of MSSA collected from bacteraemia cases in the United Kingdom and Ireland during 2001-2006 were resistant to gentamicin [2, 11] . On the other hand, recent studies from the Middle East showed a high incidence of aminoglycoside-resistant S. aureus [12, 13] . In Greece, until now there was little information about the rates of aminoglycoside-resistant S. aureus. A previous study conducted in Central Greece during 2000 revealed that 11.2% and 18% of S. aureus exhibited resistance to gentamicin and tobramycin, respectively [14] . Comparing these results with our present data, an inversion of the resistant phenotypes is observed, with a decrease of gentamicin and tobramycin-resistance (6.3% and 12.9%, respectively) followed by a significant increase of kanamycin and amikacin resistance (48.2% for both agents versus 29.2% in 2000), partially due to the predominance of the ST80 MRSA clone in the country [14, 15] . In addition, in contrast to other studies, the aph(3′)-IIIa was the most prevalent AMEs gene (73.3%) in our strains [2, 12, 13] . The significant differences of the resistance rate and AME gene distribution of S. aureus among Greek regions may be due to the predominance of specific clones and to aminoglycoside usage in each clinical setting combined with a possible horizontal AME gene transfer, as reflected in the results of participating hospitals.
Concerning the rate of aminoglycoside-resistant CoNS, previous studies showed that they were more often aminoglycoside-resistant than S. aureus [2, 11] . In Greece during the year 2000, 31% and 35% of S. epidermidis were resistant to gentamicin and tobramycin, respectively, while a significant increase of resistance (42.8% to both agents) was observed in S. epidermidis isolates eight years later [14, 16] . All isolates carried at least two AMEs genes. Indeed, CoNS have been frequently reported to carry resistance determinants, including genes encoding AMEs and as such have the capacity to function as a genetic reservoir. Conjugal transfer of resistance determinants between S. aureus and S. epidermidis leads to rapid dissemination of these determinants in the hospital environment.
As previously mentioned, VITEK 2 failed to detect kanamycin and amikacin resistance among S. aureus isolates carrying the aph(3′)-IIIa gene. This can be explained by the fact that kanamycin and amikacin, that are accurate indicators of aph(3′)-IIIa gene presence, were not included in the P549 card; unfortunately, the newer P490 card also does not include them. Misidentification of such strains may lead to a therapeutic failure in cases where kanamycin or amikacin are used. On the contrary, VITEK 2 correctly identified aminoglycoside-resistant phenotypes among S. epidermidis, since all resistant S. epidermidis carried at least the aac(6′)-Ie-aph(2″) gene, and thus, exhibited resistance to gentamicin and tobramycin that are included in the P549 card. Thus, we recommend that laboratories using VITEK should employ alternative susceptibility testing methods for the detection of kanamycin and amikacin resistance in S. aureus.
In conclusion, this is the first study that describes the distribution of AME genes in correlation with the rate of aminoglycoside-resistant staphylococci in Greece during a one-year period (2009), providing useful comparative data for future studies. Today, according to hospital pharmacy records, amikacin and gentamicin are widely used in our clinical settings, specifically in those where the prevalence of KPC-producer gentamicin-sensitive K. pneumoniae is high [7] . Probably, the re-introduction of these aminoglycosides in the clinical practice may enhance the emergence and dissemination of staphylococcal clones resistant to these agents. The high rate of aminoglycoside-resistant staphylococci (48.2% S. aureus and 42.8% S. epidermidis) in Greek hospitals located at different areas of the country indicates the need for accurate detection of resistance combined with knowledge of the epidemiology of such resistance determinants, in order to limit further increase and to preserve the usefulness of aminoglycosides in the treatment of complicated infections.
